A5037452752- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Advanced Breast Cancer Therapies
- Endometrial and Cervical Cancer Treatments
- Breast Cancer Treatment Studies
- Acute Lymphoblastic Leukemia research
- Ovarian cancer diagnosis and treatment
- Viral-associated cancers and disorders
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Telomeres, Telomerase, and Senescence
- Patient Satisfaction in Healthcare
- Reliability and Agreement in Measurement
- Pharmacovigilance and Adverse Drug Reactions
- CNS Lymphoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- LGBTQ Health, Identity, and Policy
- AI in cancer detection
- Intraperitoneal and Appendiceal Malignancies
- Chronic Myeloid Leukemia Treatments
- Antibiotic Use and Resistance
- Cancer-related Molecular Pathways
- Statistical Methods in Clinical Trials
- Cancer-related molecular mechanisms research
Deloitte (United States)
2022-2024
University of Rochester
2016-2020
University of Rochester Medical Center
2016-2020
We studied the risk of infections in patients with chronic lymphocytic leukemia/small lymphoma (CLL). Major were defined as requiring hospital admission or intravenous antimicrobial treatment. Incidence rate (IR) ratios (IRR) used to compare infection rates. Of 263 CLL followed for 936.9 person-years, 60% required treatment progressive (66 received ibrutinib). Infections occurred 71.9% (IR 92.4/100 person-years) 31.9% having major 20.3/100 and causing 37.5% deaths. was associated...
Antimicrobial resistance (AMR) is a global public health concern exacerbated by inappropriate antimicrobial prescribing practices, particularly in low-resource settings such as Uganda. The research aimed to develop culturally sensitive behavioral intervention, leveraging "nudge" strategy, improve healthcare provider adherence the 2016 Uganda Clinical Guidelines (UCG 2016) five Ugandan hospitals. This intervention formed part of broader stewardship initiatives led United States Agency for...
Family and migration studies suggest a genetic risk of developing chronic lymphocytic leukemia/small lymphoma (CLL). We hypothesized that CLL patients have an increased additional clonally unrelated B-cell malignancies. To test this, we studied 467 (2743 person-years (PYs)) at single institution over 17 years. The incidence rate (IR) any lymphoid malignancy was 10.9 per 1000 PYs (n = 30, 6.4%). Eighteen (4%) had (IR 6.6 PYs). Standardized ratios (SIRs) were used to compare the malignancies...
Abstract Background: Palbociclib (palbo), a CDK4/6 inhibitor, is commonly added to an aromatase inhibitor (AI) as the first line therapy in managing estrogen receptor positive, HER2 non amplified (ER+ HER2-) metastatic breast cancer (MBC). Though more tolerable than chemotherapy, palbo may need dose interruption, delay or reduction due toxicities like neutropenia. Currently, there are no clinical data on effect of relative intensity (RDI) setting outcomes. The primary objective this study...